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ABSTRACT
Historically, there have been few treatment options for
patients with advanced renal cell carcinoma (RCC) be-
sides immunotherapy with interleukin-2 and interferon
(IFN)-.Targetedtherapieshaveimprovedclinicalout-
comesoverthepastseveralyears.Theseincludethevas-
cular endothelial growth factor receptor (VEGFR)
tyrosine kinase inhibitors sunitinib and sorafenib,
which inhibit angiogenic signaling in endothelial cells
and vascular pericytes predominantly through VEGFR
and platelet-derived growth factor receptor . Also in-
cluded is the anti-VEGF monoclonal antibody bevaci-
zumab used in combination with IFN-. These agents
mediate their antitumor effects by interfering with the
VEGF signaling pathway, thereby inhibiting angiogen-
esis and causing tumor shrinkage. However, ultimately,
most patients develop resistance and experience disease
progression during VEGF/VEGFR-targeted therapy,
and until the recent approval of the mammalian target
of rapamycin (mTOR) inhibitor everolimus (RAD001),
there were no agents available with proven activity in
this setting. This review describes the clinical develop-
ment of everolimus in advanced RCC and the rationale
for the use of mTOR inhibitors after failure of VEGF/
VEGFR inhibitors. The Oncologist 2010;15:236–245
INTRODUCTION
In most clear cell renal cell carcinoma (RCC) cases, loss of
the ability to downregulate cellular responses to hypoxic
stressdrivesangiogenesisandtheprogressivegrowthofthe
tumor. Normally, the von Hippel-Lindau gene product
VHL participates in an oxygen-dependent process to target
the transcription factor hypoxia-inducible factor (HIF)-1
for proteasomal degradation. Under conditions of hypoxic
stress, HIF-1 migrates to the nucleus, where it forms a
transcriptionfactorfortheproductionofangiogenicgrowth
factors and the many other proteins involved in the cellular
hypoxic response. In normoxia, VHL prevents this stimu-
lation by removing HIF-1 before it enters the nucleus. In
clear cell RCC, cells have lost the ability to produce VHL
and the ability to downregulate the hypoxic response [1].
The new therapies that have entered the clinic over the
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the angiogenic response in RCC by inhibiting the ability of
endothelialcellstorespondtotheoverproductionofthean-
giogenic growth factors vascular endothelial growth factor
(VEGF) and platelet-derived growth factor (PDGF). Sor-
afenib and sunitinib are low-molecular-weight competitive
inhibitors of the tyrosine kinase activity of the receptors for
VEGF and PDGF present on the surface of endothelial
cells.Bothsunitinibandsorafenibalsoinhibitothercellular
kinases and may have direct effects on tumor growth, but
their activity is primarily directed at endothelial cells. Bev-
acizumab, also approved for use in RCC, is a monoclonal
antibody that binds VEGF, preventing the agent’s interac-
tion with its receptor on endothelial cells. These antiangio-
genicagentsdemonstratebetterefficacythanwithcytokine
therapies and likely extend the life of most patients. Recent
datasuggestthattheiruseinanoptimumsequencemaypro-
longthemediansurvivaltimefrominitialdiagnosisofmet-
astatic disease to 2 years. However, as information on
longer treatment with these agents becomes available, it is
increasinglyapparentthattheseagentssometimeshavesig-
nificant toxicities [2, 3] and that, as with nearly all cancer
therapies, they are not curative: patients eventually relapse
andsuccumb,andtheneedforadditionaldrugdevelopment
continues.
In tumor cells, endothelial cells, and other cells of the
tumor milieu, the synthesis of key proteins for cell growth,
cell division, and angiogenesis is controlled by the mam-
malian target of rapamycin (mTOR) kinase. mTOR func-
tionsasacentralcontroller,integratingsignalsfromgrowth
factor receptors with levels of nutrients and energy to de-
termine whether the cell has the resources to support con-
tinued cell growth and cell division. In many cancers,
including RCC, defects in pathways that signal through
mTOR (Fig. 1) [4], including angiogenic growth factor sig-
naling, drive mTOR and the resulting tumor growth. The
mTOR inhibitors temsirolimus and everolimus inhibit in-
appropriate mTOR signaling and have been approved for
the treatment of RCC. Everolimus is specifically ap-
provedforuseafterfailureofVEGFRtyrosinekinasein-
hibitors (sorafenib, sunitinib). This article reviews the
developmentoftheseagentsandtheoptimizationoftheir
use in RCC with emphasis on the newly approved agent,
everolimus (Afinitor; Novartis Pharmaceuticals, Inc.,
East Hanover, NJ).
VEGF/VEGFR INHIBITORS
Table 1 shows efficacy results from the pivotal trials of tar-
geted therapies. The agents were evaluated in patients with
metastatic RCC but in somewhat different populations; di-
rect comparisons are not valid, and none of the agents have
been directly compared in a single study.
Sorafenib
Sorafenib (Nexavar; Bayer Pharmaceuticals Corporation,
Wayne, NJ) inhibits the tyrosine kinase activity of the cell
surface VEGF receptors (VEGFR-1, VEGFR-2, and
VEGFR-3), PDGFR-, Fms-like tyrosine kinase 3 (Flt-3),
and stem cell factor receptor (c-Kit), and the intracellular
serine/threonine Raf kinases [5]. In its pivotal 903-patient
phase III trial, the preplanned interim analysis showed a
significantly longer progression-free survival (PFS) inter-
valwithsorafenibthanwithplacebo(5.5monthsversus2.8
months; hazard ratio [HR], 0.44; 95% confidence interval
[CI], 0.35–0.95; p  .001) in patients who had advanced
clear cell RCC that had progressed after one systemic cyto-
kine therapy regimen and were classified as good or inter-
mediate risk on the Memorial Sloan-Kettering Cancer
Center (MSKCC) prognostic survival scale for patients
with RCC (MSKCC risk score) [6]. Tumor responses were
seenin10%,and74%hadstabledisease(SD)for28days
(compared with 2% with partial responses [PRs] and 53%
with SD in the placebo group; p  .001). After a median of
23 weeks of treatment, common adverse events (AEs) of
any grade with sorafenib (30% of patients) included diar-
rhea,rash,fatigue,andhand–footsyndrome(HFS).Grade3
or 4 hypophosphatemia, elevated lipase, and HFS occurred
in 13%, 12%, and 6% of these patients, respectively. Dose
interruptions in 21% of the sorafenib-treated patients were
principally a result of HFS and diarrhea. Rare (1%–2%) se-
rious adverse events (SAEs) included hypertension, dys-
pnea, and cardiac ischemia [7]. After the preplanned
analysis, patients in the placebo arm were allowed to cross
over to treatment with sorafenib. At the final data cutoff 16
months after crossover, the survival time in the sorafenib-
treated cohort was 17.8 months, compared with 15.2
months for the placebo group (HR, 0.88; 95% CI, 0.74–
1.04; p  .146). After censoring of the crossover patients,
the estimated overall survival (OS) duration for the place-
bo-treated patients was only 14.3 months (HR, 0.78; CI,
0.62–0.97; p  .0287) [3]. In December 2005, the U.S.
Food and Drug Administration (FDA) granted approval for
the use of sorafenib in patients with advanced RCC; sor-
afenib was later approved by the European Medicines
Agency (EMEA) (July 2006) for use in patients who have
advanced RCC after failure of cytokine-based therapy or
who are considered unsuitable for such therapy.
Sunitinib
Sunitinib (Sutent; Pfizer Inc., New York) received U.S.
regulatory approval for use in advanced RCC in January
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Sunitinib principally inhibits the tyrosine kinase activity of
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-, PDGFR-,
c-Kit, Flt-3, and RET, and to a lesser extent the activity of
several other kinases [5]. In its pivotal phase III trial,
sunitinib was compared with interferon IFN- in the first-
line treatment of 750 patients with mostly good- and inter-
mediate-risk metastatic RCC, and was found to result in a
significantly longer PFS interval (11 months versus 5
months; HR, 0.42; 95% CI, 0.32–0.54; p  .001) [8]. Ob-
jective responses (PRs) occurred in 31% of patients treated
with sunitinib, compared with 6% of patients treated with
IFN- (p  .001). Treatment-related AEs occurred more
frequently with sunitinib than with IFN-. After a median
of6monthsoftreatment,commonAEsofanygradeduring
treatment with sunitinib (30% of patients) included diar-
Figure 1. PI3K/Akt/mTOR pathway signaling in tumor and vascular endothelial cells. The PI3K/Akt/mTOR pathway (A) and
molecular targets for treatment in renal cell carcinoma (B).
Abbreviations: 4E-BP1, eukaryotic initiation factor 4E binding protein 1; HIF, hypoxia-inducible factor; mTOR, mammalian
target of rapamycin; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; PI3K, phosphatidylinositol 3-kinase; S6K1,
S6 kinase 1; TSC, tuberous sclerosis complex; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VHL, von
Hippel-Lindau.
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declined in 10% of patients (3% of those treated with IFN-
), but grade 3 decreases were rare (2%). Grade 3 or 4
events with sunitinib (7% of patients) included increased
lipase (13%), lymphopenia (12%), neutropenia (11%), hy-
pertension (8%), thrombocytopenia (8%), and fatigue
(7%). Among the sunitinib-treated patients, 38% had dose
interruptions resulting from AEs [8].
In the final analysis, the median OS time with sunitinib
(26.4 months) was longer than that with IFN- (21.8
months) (HR, 0.821; 95% CI, 0.673–1.001; p  .051) [2].
Sunitinib is occasionally associated with prolongation of
the QT interval on electrocardiography. It is recommended
that sunitinib not be used in patients with congestive heart
failure and be used with caution in patients who have had
cardiac events within 12 months of initiating therapy. Hy-
pothyroidism increases with the length of exposure to
sunitinib[9],anditisofinterestthatsunitinibisbeingstud-
ied in patients with thyroid cancer.
Pazopanib
Pazopanib (Votrient
TM; GlaxoSmithKline, London, UK) is a
selectiveinhibitorofVEGFR-1,VEGFR-2,VEGFR-3,c-Kit,
PDGFR- and PDGFR-. It was tested in comparison with
placebo in a randomized phase III study in 233 treatment-
naïve and 202 cytokine-pretreated patients with advanced
RCC. In a preliminary report from that study, the median PFS
interval in treatment-naïve patients was 11.1 months with pa-
zopanib, compared with 2.8 months with placebo (HR, 0.40;
95%CI,0.27–0.60;p.0000001).Inthecytokine-pretreated
patients, the PFS intervals were 7.4 months with pazopanib
and 4.2 months with placebo (HR, 0.54; 95% CI, 0.35–0.84;
p  .001). These results are comparable with those seen with
sorafenib and sunitinib in similar groups of patients [10].
Table 1. Phase III trials in patients with advanced RCC
Study Agents Line Patients PFS (mos) OS (mos) ORR (%)
Motzer et al. [8] Sunitinib First line All risk groups 11.0 26.4 31
IFN- 5.0 21.85 6
HR, 0.42;
p  .001
HR, 0.82;
p  .051
p  .001
Escudier et al. [12] Bevacizumab 
IFN-
First line All risk groups 10.2 23.3 31
IFN- 5.4 21.3 13
HR, 0.63;
p  .0001
HR, 0.86;
p  .129
p  .0001
Rini et al. [14] Bevacizumab 
IFN-
First line All risk groups 8.5 18.3 25.5
Placebo 5.2 17.4 13.1
HR, 0.71;
p  .0001
HR, 0.86;
p  .069
p .0001
Hudes et al. [27] Temsirolimus First line Intermediate
and poor risk
3.1 10.9 8.6
IFN- 5.5 7.3 4.8
NR HR, 0.73;
p  .008
NR
Escudier et al. [7] Sorafenib Second line Good and
intermediate
risk
5.5 17.8 10
Placebo 3.1 15.2 2
HR, 0.44;
p  .001
HR, 0.88;
p  .146
p .001
Motzer et al. [36] Everolimus Second line All risk groups,
VEGFR TKI
failure
4.0 NR 1
Placebo 1.9 NR 0
HR, .30;
p  .0001
NR
Abbreviations: HR, hazard ratio; IFN-, interferon ; NR, not reported; ORR, overall response rate; OS, overall survival;
PFS, progression-free survival; RCC, renal cell carcinoma; VEGFR TKI, vascular endothelial growth factor receptor
tyrosine kinase inhibitor.
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Bevacizumab (Avastin; Genentech Inc., South San Fran-
cisco, CA) is a humanized monoclonal antibody against
VEGF-A that prevents VEGF-A stimulation of its receptor
(VEGFR-2) on endothelial cells. Bevacizumab is approved
in Europe (2007) and the U.S. (2009) for use with IFN- in
patients with previously untreated metastatic RCC. Two
phase III trials compared IFN- plus bevacizumab with
IFN- alone in previously untreated patients with meta-
static RCC and predominantly favorable and intermediate
MSKCC risk scores [11]. The Avastin and Roferon in Re-
nal Cell Carcinoma (AVOREN) trial, conducted mainly in
Europe, compared bevacizumab plus IFN- with placebo
plus IFN- in 649 patients and showed that bevacizumab
treatment led to a significantly longer PFS interval (10.2
months, versus 5.4 months; HR, 0.63; p  .0001) [12]. The
overallresponserate(ORR)inthebevacizumabplusIFN-
group was 31%, versus 13% in the placebo plus IFN-
group (p  .0001), with SD in 46% of patients. After a me-
dian of 9.7 months of treatment, common treatment-related
AEs of any grade (30% of patients) included pyrexia, an-
orexia, bleeding, fatigue, and asthenia. Frequent grade 3 or
4 toxicities (7% of patients) included fatigue (12%), as-
thenia (10%), and proteinuria (7%). In the final data analy-
sis, the median survival times were 23.3 months in the
bevacizumabarmand21.3monthsintheplaceboarm(HR,
0.86; 95% CI, 0.72–1.04; p  .1291) [13].
The trial conducted in the U.S. (Cancer and Leukemia
Group B [CALGB] 90206) compared bevacizumab plus
IFN- (same doses as in the AVOREN study) with IFN-
monotherapyin732patients.ThePFSintervalwithbevaci-
zumab plus IFN- was 8.5 months, compared with 5.2
months with IFN- alone (HR, 0.71; 95% CI, 0.61–0.83;
p  .0001). There was also a higher ORR with bevaci-
zumab plus IFN- (25.5%) than with IFN- monotherapy
(13.1%; p  .0001). The difference in the PFS time and
ORRbetweenthetwotrialsmayreflectaworserisk–group
distribution of treated patients, the absence of nephrectomy
in the majority of patients, and the possibility of a lower
proportion of tumors of strictly clear cell histology in the
CALGB trial. Frequent grade 3 or 4 toxicities (7% of pa-
tients) in the bevacizumab plus IFN- group included fa-
tigue (35%), anorexia (17%), proteinuria (15%), and
hypertension (9%) [14].
Unfortunately, neither trial included a bevacizumab
only arm, so the relative contribution of IFN- to the regi-
men remains an open question.
Sorafenib, sunitinib, and bevacizumab plus IFN- have
substantiallyimprovedonthe6.5%–7.5%responserateand
about doubled the 12- to 13-month OS time historically
achieved with interleukin (IL)-2 or IFN- cytokine therapy
in patients with advanced RCC [15]. Studies have shown
that, somewhat contrary to the expectation of common
mechanisms of resistance [16], sorafenib and sunitinib do
not appear to be entirely crossresistant. Patients whose tu-
mors progress on either sorafenib or sunitinib may benefit
from subsequent treatment with the other agent [17–21]. In
studies in which patients began therapy with sorafenib or
sunitinib and were switched to the other agent at progres-
sion, the median OS time was 24–30 months, approxi-
mately the same OS time seen with first-line sunitinib or
bevacizumab plus IFN- [18, 21]. Although this is encour-
aging, it is reasonable to expect that expanding the antitu-
moreffectsbeyondVEGF/VEGFRinhibitionmayproduce
more encouraging results.
The mTOR inhibitors are also approved for the treat-
ment of patients with advanced RCC. Everolimus and tem-
sirolimus have direct antitumor effects through inhibition
of the protein synthesis required for tumor cell growth and
proliferation, they directly inhibit angiogenesis through the
sameeffectsonendothelialcellsandothercellsinvolvedin
neovascularization (pericytes), and they have indirect ef-
fects in inhibiting the synthesis of the growth factors that
tumor cells require for their own growth and angiogenesis
(VEGF, PDGF, fibroblast growth factor [FGF], transform-
inggrowthfactor-)[22,23].Becausetheantitumormech-
anisms of these agents complement and extend those of
sorafenib, sunitinib, and bevacizumab with little overlap in
theirsafetyprofiles,sequentialorcombinationtherapywith
these agents is being investigated as a rational option to be
used early in the sequence of treatments for metastatic
RCC.
MTOR AND MTOR INHIBITORS
The mTOR kinase integrates signals relating to energy, nu-
trients,andoxygentodeterminewhetherthecellhasthere-
sources to grow and divide in response to growth factor
stimulation (Fig. 1A). Positive signals allow mTOR to act
on its targets S6 kinase 1 (S6K1), which activates the ribo-
somal S6 protein and ribosomal synthesis, and eukaryotic
translation initiation factor 4E binding protein (4E-BP1),
which when activated allows transcription of the proteins
involvedintheregulationofcellgrowth,cellcycleprogres-
sion, and cellular metabolism. Through the synthesis of
HIF-1, mTOR controls the production of proteins involved
in angiogenesis (e.g., VEGF) and other responses that in-
crease supplies of nutrients and energy for growing cells
[24, 25]. mTOR is highly conserved from fungi to mam-
mals,andmutationsinmTORarelethalveryearlyindevel-
opment, which is particularly significant in that the
signalingpathwaysthatconvergeonmTORarethemselves
dysregulated in most cancer cells [4]. Defects in the signal-
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pressorgenes,oncogenes,andgrowthfactorreceptors,may
be required events in tumorigenesis [22]. Inappropriate ac-
tivation of the mTOR signaling pathway in the pathogene-
sis of cancer often correlates with a more aggressive tumor
and a worse prognosis [4].
Rapamycin and its analogs form an intracellular com-
plex with a 12-kDa cytosolic protein, FKBP12 (FK506
binding protein), that inhibits mTOR activity and prevents
activation of S6K1, which, in addition to activating the ri-
bosomal S6 protein, has a negative feedback effect on Akt/
protein kinase B (Akt). Consequently, mTOR inhibition
enhances Akt activity, with the potential to promote cancer
cell survival and chemoresistance. However, although the
effect of Akt activation by mTOR inhibitors is an area of
research interest, it has not been shown to affect clinical re-
sponsesanditisnotyetclearwhetheritisacommonmech-
anism or limited to certain types of cells or certain
physiologic conditions. It has been suggested that pro-
longed exposure to mTOR inhibitors may decrease Akt ac-
tivitythrougheffectsonTORC2,therapamycin-insensitive
mTOR complex [26].
mTOR inhibitors are being investigated as anticancer
agents based on their capacity to act directly on tumor cells
byinhibitingtumorcellgrowthandproliferation,aswellas
for their ability to inhibit angiogenic activity by both direct
effects on vascular cell proliferation and indirect effects on
growth factor production (Fig. 1B).
Temsirolimus
Temsirolimus, a prodrug converted in vivo to rapamycin,
wasformulatedfori.v.administration.Itwasevaluatedina
phase III trial with randomization to temsirolimus (25 mg
weekly), IFN- (3–18 MU 3 times a week [tiw]), or a com-
bination of 15 mg weekly temsirolimus and a reduced dose
of IFN- (3–6 MU tiw). The trial enrolled 626 previously
untreated patients, 80% with metastatic clear cell RCC and
74% in the MSKCC poor-risk category [11]. Treatment
withtemsirolimusledtoasignificantlylongerOStimethan
with IFN- alone (10.9 months versus 7.3 months; HR,
0.73; p  .008), and the PFS interval was 5.5 months with
temsirolimus,versus3.1monthswithIFN-.TheORRwas
8.6%,andSDfor6monthswasseenin23.5%ofpatients.
Commontreatment-relatedAEsofanygrade(30%ofpa-
tients) included asthenia, rash, anemia, nausea, and an-
orexia. Frequent grade 3 or 4 toxicities (7% of patients)
included anemia (20%), asthenia (11%), hyperglycemia
(11%), and dyspnea (9%) [27]. Further analysis identified
noninfectious pneumonitis/interstitial lung disease as a po-
tential SAE [28].
InMay2007,temsirolimusreceivedU.S.regulatoryap-
proval for metastatic RCC, and it was approved by the
EMEA in November 2007 for use limited to the first-line
treatment of poor-risk patients. A subgroup analysis of
the phase III data [29] presented at the 2007 meeting of the
AmericanSocietyofClinicalOncologysuggestedthattem-
sirolimus may be as effective against non–clear cell RCC
(HR, 0.55; 95% CI, 0.33–0.90) as against clear cell RCC
(HR, 0.85; 95% CI, 0.67–1.08), but the number of non–
clear cell patients was too small to draw definitive conclu-
sions. Although this observation may actually reflect the
limited activity of IFN- in non–clear cell RCC, it could
also indicate that mTOR inhibitors have activity in a
broader group of RCC patients in whom tumor growth is
driven by mechanisms other than VHL mutations. This
question is currently being addressed in clinical trials.
Everolimus
Everolimus has been formulated for oral administration
with a dosing strategy developed in phase I clinical trials
[30]. Everolimus is a derivative of rapamycin and is not
converted to rapamycin in vivo. Everolimus has been in
clinical development since 1996 as an immunosuppressant
in solid organ transplantation and has obtained marketing
authorization (Certican; Novartis Pharmaceuticals, Inc.,
East Hanover, NJ) for prophylaxis of rejection in renal and
cardiac transplantation in Europe.
Everolimus Phase I Clinical Development
Phase I studies determined the optimum dose and regimen
of everolimus used in subsequent trials. Phase I clinical
studies and preclinical–clinical pharmacokinetic–pharma-
codynamic modeling [31, 32] predicted that a 5- to 10-mg
Figure 2. Consistent sustained inhibition of S6 kinase 1
(S6K1) by everolimus with daily versus weekly dosing.
From Tanaka C, O’Reilly T, Kovarik JM et al. Identifying
optimal biologic doses of everolimus (RAD001) in patients
with cancer based on the modeling of preclinical and clinical
pharmacokinetic and pharmacodynamic data. J Clin Oncol
2008;26:1596–1602. Reprinted with permission from the
American Society of Clinical Oncology. All rights reserved.
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ration)ofmTORanditsdownstreamtargetsthanwouldthe
same dose on a weekly schedule (Fig. 2) [32]. Subsequent
studies confirmed that 10 mg/day was the optimum daily
dose for phase II monotherapy studies with everolimus
[22]. Phase I studies also assessed the effects of everolimus
on mTOR activity in tumors from treated patients and con-
firmed that daily dosing resulted in profound and sustained
inhibition of mTOR activity in tumor tissue [33]. The 30-
hour half-life of everolimus is compatible with daily dos-
ing,and5–10mg/daysustainsthecirculatingconcentration
(trough) of everolimus above the minimum effective con-
centration and minimizes drug peaks that could potentially
exacerbate toxicity. Of note, the advantage of continuous
dosing over an intermittent regimen is also being investi-
gated with sunitinib in RCC patients to avoid the treatment
breaks with the 4-weeks-on-2-weeks-off regimen, to possi-
bly reduce toxicity, and to allow combination with other
agents [34].
Clinical Activity of Everolimus in RCC
In phase I studies, 147 patients with advanced solid tumors
refractory to standard therapy were treated with everolimus
either as single weekly (20 mg, 50 mg, and 70 mg) or con-
tinuous daily (5 mg and 10 mg) oral doses until progression
[31, 33]. Among the 147 patients, 12 had metastatic RCC
(8.2%ofthetotalstudypopulation).OneRCCpatienthada
PR (8.3%), six were progression free at 6 months (50%),
and four were progression for 12 months (33.3%).
A phase II study to assess the safety and efficacy of 10
mg/day oral everolimus in 41 mostly pretreated patients
with advanced clear cell RCC was started in 2005, before
the approval of sorafenib and sunitinib. There was no lim-
itationbasedonMSKCCriskscore,and83%ofthepatients
had received prior therapy, with 61% having received cy-
tokine therapy with IL-2 and/or IFN- [35]. Fifty-seven
percent of patients remained progression free for 6
months, with a median PFS interval of 11.2 months and a
median OS time of 22.1 months. The ORR was 14% (all
PRs), and 73% of patients had SD for 3 months. Overall,
70%ofpatientshadeitheraresponseorSDfor6months.
This small phase II study supported the efficacy of everoli-
mus in patients previously treated with cytokine therapy.
Common treatment-related AEs (30% of patients) were
anorexia, nausea, diarrhea, stomatitis, and pneumonitis.
Grade 3 pneumonitis (18%) resulted in dose delays of 7–14
days and a dose reduction for seven patients, four of whom
were successfully re-escalated to 10 mg/day. Grade 3 bio-
chemical abnormalities included alanine aminotransferase
elevation (10%), alkaline phosphatase elevation (8%), hy-
perglycemia (8%), and thrombocytopenia (8%).
The encouraging phase II results led to the design of a
pivotalphaseIIIinvestigationoforaleverolimusinpatients
with advanced RCC progressing after failure of treatment
with sunitinib and/or sorafenib (Renal Cell Carcinoma
Treatment with Oral RAD001 Given Orally, RECORD-1).
When that trial began, sunitinib and sorafenib were both
first-line treatment options for metastatic RCC, and this
wasthefirstrandomizedstudytoassessanmTORinhibitor
in this patient population [36]. Four hundred ten patients
with clear cell RCC that had progressed within 6 months of
stopping treatment with sorafenib, sunitinib, or both drugs
were randomly assigned in a 2:1 ratio to receive everoli-
mus, 10 mg once daily (n  272), or placebo (n  138) in
conjunction with best supportive care. Everolimus treat-
ment resulted in a significantly longer median PFS interval
thanwithplacebo(4.0monthsversus1.9months;HR,0.30;
95%CI,0.22–0.40;p.0001)inpatientswithprogression
after VEGFR tyrosine kinase inhibitor therapy (Fig. 3).
There was no difference based on prior therapy or MSKCC
risk score, and clinical benefit was maintained across all
subgroups [36]. In an updated data analysis performed 8
monthslater,themedianPFStimewitheverolimuswas4.9
months, versus 1.9 months in the placebo-treated patients
(HR, 0.33; 95% CI, 0.25–0.43; p  .001), and 69% of the
277 everolimus-treated patients had either responded (2%)
or had SD for 2 months [37]. Everolimus had a positive
effect on patient survival (HR, 0.87; 95% CI, 0.65–1.15;
p.162)despitethecrossoverdesign,andwhencrossover
patientswerecensoredfromtheanalysis,theestimatedme-
dian survival time of the everolimus-treated patients was
14.8 months, compared with 10.0 months for those treated
with placebo [38].
The safety profile of everolimus in this pretreated pop-
Figure 3. Kaplan–Meier estimates of progression-free sur-
vival.
From Motzer RJ, Escudier B, Oudard S et al. Efficacy of
everolimus in advanced renal cell carcinoma: A double-blind,
randomised, placebo-controlled phase III trial. Lancet 2008;
372:449–456. Reprinted with permission from Elsevier.
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grade included stomatitis (40%), rash (25%), and fatigue
(20%). Frequent grade 3 or 4 toxicities included stomatitis
(3%), infections (grade 3, 2%; grade 4, 1%), and noninfec-
tious pneumonitis (3%). Grade 3 or 4 laboratory abnormal-
ities (1% of patients) included lymphopenia (grade 3,
14%; grade 4, 1%), hyperglycemia (12%), hypophos-
phatemia (4%), and hypercholesterolemia (3%) [36]. Non-
infectious pneumonitis is a toxicity associated with mTOR
inhibition. It is a nonmalignant infiltration in the lungs, ev-
ident radiologically, usually nonsymptomatic (grade 1) or
associated with minimal symptoms (grade 2), and revers-
ible with drug discontinuation. Patients receiving mTOR
inhibitors should be monitored for development of pneu-
monitis, and those with evidence of disease should have
their dose reduced or stopped until recovery to grade 1.
Table 2. Treatment-related adverse events associated with everolimus
Adverse event
Everolimus group (n  269) Placebo group (n  135)
All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Stomatitis
a,b 107 (40%) 9 (3%) 0 11 (8%) 0 0
Rash 66 (25%) 2 (1%) 0 6 (4%) 0 0
Fatigue 53 (20%) 8 (3%) 0 22 (16%) 1 (1%) 0
Asthenia 48 (18%) 4 (1%) 0 11 (8%) 1 (1%) 0
Diarrhea 46 (17%) 4 (1%) 0 4 (3%) 0 0
Anorexia 44 (16%) 1 (1%) 0 8 (6%) 0 0
Nausea 41 (15%) 0 0 11 (8%) 0 0
Mucosal inflammation 39 (14%) 3 (1%) 0 3 (2%) 0 0
Vomiting 32 (12%) 0 0 5 (4%) 0 0
Cough 32 (12%) 0 0 5 (4%) 0 0
Dry skin 29 (11%) 1 (1%) 0 5 (4%) 0 0
Infections
a,c 27 (10%) 6 (2%) 3 (1%) 3 (2%) 0 0
Pneumonitis
d 22 (8%) 8 (3%) 0 0 0 0
Dyspnea 22 (8%) 4 (1%) 0 3 (2%) 0 0
Laboratory abnormality
Anemia 244 (91%) 24 (9%) 1 ( 1%) 103 (76%) 7 (5%) 0
Hypercholesterolemia
a 205 (76%) 9 (3%) 0 43 (32%) 0 0
Hypertriglyceridemia 191 (71%) 2 (1%) 0 41 (30%) 0 0
Hyperglycemia
a 135 (50%) 31 (12%) 0 31 (23%) 2 (1%) 0
Raised creatinine 125 (46%) 1 ( 1%) 0 44 (33%) 0 0
Lymphopenia
a 114 (42%) 38 (14%) 4 (1%) 39 (29%) 7 (5%) 0
Raised alkaline phosphatase 101 (37%) 2 (1%) 0 40 (30%) 2 (1%) 0
Hypophosphatemia
a 87 (32%) 12 (4%) 0 9 (7%) 0 0
Leukopenia 70 (26%) 0 0 11 (8%) 0 1 (1%)
Raised aspartate aminotransferase 56 (21%) 1 (1%) 0 9 (7%) 0 0
Thrombocytopenia 55 (20%) 2 (1%) 0 3 (2%) 0 1 (1%)
Raised alanine aminotransferase 48 (18%) 1 (1%) 0 5 (4%) 0 0
Hypocalcemia 46 (17%) 0 0 8 (6%) 0 0
Neutropenia 29 (11%) 0 0 4 (3%) 0 0
aSum of grade 3 and 4 events significantly different between everolimus group and placebo group (two-sided Fisher’s exact
test): stomatitis, p  .03; infections, p  .03; hypercholesterolemia, p  .03; hyperglycemia, p  .0001; lymphopenia, p 
.002; hypophosphatemia, p  .01. No adaption for multiple testing was done.
bIncludes aphthous stomatitis, mouth ulceration, and stomatitis.
cIncludes all infections.
dIncludes interstitial lung disease, lung infiltration, pneumonitis, pulmonary alveolar hemorrhage, and pulmonary toxicity.
From Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind,
randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456. Reprinted with permission from Elsevier.
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provided the noninfectious origin is confirmed [28].
Everolimus has received FDA (March 2009) and
EMEA (May 2009) approval for the treatment of patients
withadvancedRCCafterfailureoftreatmentwithsunitinib
or sorafenib. Based on the trial data, everolimus also re-
ceived a category 1 recommendation by the National Com-
prehensive Cancer Network for the second-line treatment
of patients with advanced RCC after failure of tyrosine ki-
nase therapy [39].
PERSPECTIVES
With the availability of sunitinib, sorafenib, bevacizumab,
temsirolimus, and everolimus for metastatic RCC, this dis-
easehasbeentransformedfromonewithtoofewoptionsto
one with many options and a critical need for more re-
search. Sequential treatment with these agents after disease
progression to overcome resistance has become the usual
clinical practice, but a great amount of work is still needed
to determine whether existing agents may work better in
combination or whether one specific sequence of these
agentsissuperiortoanother,assuggestedinearlytrials[18,
21]. Another urgent question is the nature of the resistance
to VEGF/VEGFR-targeted therapies. Proposed mecha-
nisms have focused on enhanced angiogenic signaling.
Suggestions supported by experimental studies include the
upregulationofHIF-1toenhancethehypoxicresponseby
greatlyincreasinglevelsofVEGFandPDGFandotherfac-
tors needed for cell proliferation, and the upregulation of
alternate proangiogenic pathways through other cell sur-
face receptors such as those for FGF, insulin-like growth
factor, ephrins, and angiopoietins [16]. The basis of current
research combining everolimus or temsirolimus with bev-
acizumab and exploring optimal sequencing of the mTOR
inhibitors with sunitinib and sorafenib is twofold: the ex-
pectation of additional antitumor effects with mTOR inhi-
bition,aswellascomplementaryangiogenicactivities[40],
and the position of mTOR downstream in the signaling
pathwaysfromVEGFRandPDGFRanddownstreaminthe
proposed alternate angiogenic signaling pathways.
The coming years will be even more exciting for RCC,
and it is hoped that ongoing clinical trials will clarify some
of the issues related to potential combinations and new
drugs that have shown promise in phase II studies.
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